entertainment -WSS

entertainment

author：comprehensive 2025-09-29 19:05:28 - browse：83766

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Ascension's ugly legal battle over care for poor patients in Texas

hotspot

WSS

Medical experts are missing from AI regulatory conversations

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Gene therapy denied for Afghan refugee whose father aided U.S.

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Why the Crimean Bridge is key to Russia's war in Ukraine

Wikipedia

entertainment

entertainment

Continuity nursing helped my family in our darkest PICU moments

Medicare Advantage coverage denials need scrutiny, senators say

The cancer drug shortage isn’t new — and neither are the solutions

Male doctors called my cancer incurable. A female doctor showed it wasn't

Virginia high school admissions case could be legal follow

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Affirmative action in medical school literally saved lives

Celebrate National Dole Whip Day for 3 days this week at Disney

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA early review: GLP

focus

Stanford updates investigation of president’s past research

Male doctors called my cancer incurable. A female doctor showed it wasn't

Study suggests new cause of Down syndrome: cells linked to aging

Ascension's ugly legal battle over care for poor patients in Texas

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Hospital chaplains balance Covid safety with patients’ spiritual needs

knowledge

hotspot

hotspot

hotspot